These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31320109)

  • 41. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies.
    Vermeire S; van Assche G; Rutgeerts P
    Aliment Pharmacol Ther; 2007 Jan; 25(1):3-12. PubMed ID: 17229216
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclosporine for induction of remission in Crohn's disease.
    McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mild Crohn's Disease: Definition and Management.
    Claytor J; Kumar P; Ananthakrishnan AN; Colombel JF; Agrawal M; Ungaro RC
    Curr Gastroenterol Rep; 2023 Mar; 25(3):45-51. PubMed ID: 36753033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maintenance of remission in Crohn's disease.
    Gonvers JJ; Juillerat P; Mottet C; Felley C; Burnand B; Vader JP; Michetti P; Froehlich F
    Digestion; 2005; 71(1):41-8. PubMed ID: 15711049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.
    Sands BE; Sandborn WJ; Van Assche G; Lukas M; Xu J; James A; Abhyankar B; Lasch K
    Inflamm Bowel Dis; 2017 Jan; 23(1):97-106. PubMed ID: 27930408
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of methotrexate in patients with inflammatory bowel diseases.
    Preiss JC; Zeitz M
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S151-5. PubMed ID: 21044450
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus.
    Steinhart AH; Panaccione R; Targownik L; Bressler B; Khanna R; Marshall JK; Afif W; Bernstein CN; Bitton A; Borgaonkar M; Chauhan U; Halloran B; Jones J; Kennedy E; Leontiadis GI; Loftus EV; Meddings J; Moayyedi P; Murthy S; Plamondon S; Rosenfeld G; Schwartz D; Seow CH; Williams C
    J Can Assoc Gastroenterol; 2018 Dec; 1(4):141-154. PubMed ID: 31799497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 51. American Gastroenterological Institute Guideline on the Management of Crohn's Disease After Surgical Resection: Clinical Decision Support Tool.
    American Gastroenterological Association
    Gastroenterology; 2017 Jan; 152(1):276. PubMed ID: 27987625
    [No Abstract]   [Full Text] [Related]  

  • 52. American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection.
    Regueiro M; Velayos F; Greer JB; Bougatsos C; Chou R; Sultan S; Singh S
    Gastroenterology; 2017 Jan; 152(1):277-295.e3. PubMed ID: 27840073
    [No Abstract]   [Full Text] [Related]  

  • 53. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
    Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
    Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease.
    Lichtenstein GR
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S23-9. PubMed ID: 11380040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease.
    Grover Z; Burgess C; Muir R; Reilly C; Lewindon PJ
    J Crohns Colitis; 2016 Oct; 10(10):1159-64. PubMed ID: 26980840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective.
    Axelrad JE; Roy A; Lawlor G; Korelitz B; Lichtiger S
    World J Gastroenterol; 2016 Dec; 22(46):10103-10117. PubMed ID: 28028358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managing complicated Crohn's disease in children and adolescents.
    Homan M; Baldassano RN; Mamula P
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):572-9. PubMed ID: 16327836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.
    Loftus EV; Johnson SJ; Yu AP; Wu EQ; Chao J; Mulani PM
    Eur J Gastroenterol Hepatol; 2009 Nov; 21(11):1302-9. PubMed ID: 19465858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.